Chardan Capital Maintains Buy Rating for Pear Therapeutics: Here's What You Need To Know

Chardan Capital has decided to maintain its Buy rating of Pear Therapeutics PEAR and lower its price target from $16.00 to $13.00.

Shares of Pear Therapeutics are trading up 9.75% over the last 24 hours, at $3.94 per share.

A move to $13.00 would account for a 229.95% increase from the current share price.

About Pear Therapeutics

Pear Therapeutics Inc is engaged in developing and commercializing software-based medicines, called prescription digital therapeutics. It focuses to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.